A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Phase 1

Recruiting

• Conditions: Cystic Fibrosis
• Interventions: Biological: KB407 (Nebulization)

• Registration Number: NCT05504837
• Lead Sponsor: Krystal Biotech, Inc.

Brief Summary

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-08-15
• Study First Submitted QC: 2022-08-15
• Study First Posted: 2022-08-17
• Study Start: 2023-06-30
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-08
• Last Update Posted: 2024-04-09
• Primary Completion: 2024-07
• Study Completion: 2024-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions

2. Subjects aged 18 years or older at the time of Informed Consent

3. A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:

   • A historical sweat chloride value >60 mmol/L
   • Two copies of a disease causing mutation in the CFTR gene

4. Clinically stable in the opinion of the Investigator

5. Percent predicted FEV1 ≥50% and ≤100% of the predicted normal for age, gender, and height at Screening

6. Resting oxygen saturation ≥92% on room air at Screening

Read More

Exclusion Criteria

1. Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
2. Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
3. Treatment for Burkholderia cenocepacia, Burkholderia dolosa, or Nontuberculosis Mycobacteria infection within 3 months prior to the first dose
4. Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
5. History of or listed for solid organ transplantation
6. Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
7. An active oral herpes infection 30 days prior to the first dose
8. Has received a vaccine within 72 hours prior to the first dose or has a planned vaccination during the treatment period
9. Women who are pregnant or nursing
10. Subject who is unwilling to comply with contraception requirements per protocol
11. Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
12. Subject has a known hypersensitivity to inhaled glycerol
13. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
14. Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 3 (open label)	KB407 (Nebulization)	Four administrations of KB407
Cohort 2 (open label)	KB407 (Nebulization)	Two administrations of KB407
Cohort 1 (open label)	KB407 (Nebulization)	A single administration of KB407

Primary Outcome Measures

Name	Time	Method
To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results	2 months	Number of adult subjects with treatment related adverse events as assessed by NCI-CTCAE v5

Secondary Outcome Measures

Name	Time	Method
To evaluate the effects of KB407 on pulmonary function, as measured by change from baseline in absolute and percent predicted FEV1	2 months	Assessment of forced expiratory volume, in one second (FEV1,) will be assessed by spirometry as compared to baseline

Trial Locations

Locations (2)

The Cystic Fibrosis Institute; 🇺🇸 Northfield, Illinois, United States

Yale University School of Medicine; 🇺🇸 New Haven, Connecticut, United States